Press release, 1 May 2022
AltiVate® Reverse Shoulder system and EMPOWR™ Knee system enhance the Mathys portfolio
The Swiss prothesis expert is expanding its portfolio to include the AltiVate Reverse Shoulder and the EMPOWR Knee joint replacement systems, which will be available from May 1, 2022.
The AltiVate Reverse Shoulder: helping patients and clinicians reach higher
Mathys is proud to be launching the Altivate Small Shell stem as an extension to the AtiVate Reverse Shoulder system. This addition enhances the AltiVate Reverse® system to have more options to meet the needs of patients across a wide spectrum of humeral anatomies. The AltiVate Reverse combines enhanced fixation technologies and precision instrumentation to achieve an exceptional fit and help restore patient mobility. The AltiVate Reverse Shoulder builds on the clinical success of DJO’s RSP implant – the first reverse shoulder implant to successfully incorporate a lateralised centre of rotation (COR). The stem design is based on CT scan studies that determined the optimal shell-to-stem position and the best possible anatomical fit.
The AltiVate Reverse Shoulder features a humeral neck-shaft angle of 135°, which has been shown to reduce inferior scapular notching, resulting in improved clinical outcomes. With a total of seven glenosphere sizes, maximum COR compatibility is achieved. The AltiVate Reverse Shoulder system enhances short-term and long-term fixation on both the glenoid and humeral sides, thanks to the stable initial fixation and conditions that foster bony ingrowth. A variety of intraoperative options are offered, meaning it can be adapted to complex anatomies and deliver the best possible results for both patients and clinicians.
Media contact
AltiVate Reverse Shoulder
Ann Scobie
Product Manager Shoulder
Marketing International
Mathys Ltd Bettlach
Robert Mathys Strasse 5
2544 Bettlach
Switzerland
About
Mathys Ltd Bettlach
Mathys is committed to motion worldwide. Founded in 1946, the company has been active in medical technology since 1958 and focuses on the development, manufacture and distribution of joint replacement products. The company’s services include implants for hip, knee, shoulder and sports orthopaedics, and synthetic bone graft substitute. Headquartered in Bettlach, Switzerland, Mathys has development and production sites in Switzerland and Germany, as well as subsidiaries in 11 countries, and has been part of the US-based company Enovis™ since 2021. Enovis is committed to measurably improving patient outcomes by developing specialised solutions to clinical problems.
